New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standi...(dult and pediatric patients with moderat...),Health

active CD who have had an inadequate response to conventional therapy.

-- Reducing the number of draining enterocutaneous and rectovaginal

fistulas and maintaining fistula closure in adult patients with

fistulizing CD.

-- Reducing signs and symptoms, inducing and maintaining clinical

remission and mucosal healing, and eliminating corticosteroid use in

patients with moderately to severely active UC who have had an

inadequate response to conventional therapy.

-- Reducing signs and symptoms of active arthritis, inhibiting the

progression of structural damage and improving physical function in

patients with PsA.

-- Treatment of adult patients with chronic severe plaque PsO who are

candidates for systemic therapy and when other systemic therapies are

medically less appropriate.

REMICADE is unique among available anti-TNF biologic therapies. Unlike self-administered therapies that require patients to inject themselves frequently, REMICADE is the only anti-TNF biologic administered directly by caregivers in the clinic or office setting. REMICADE is a two-hour infusion administered every 6 or 8 weeks (indication-dependent), following a standard induction regimen that requires treatment at weeks 0, 2 and 6. As a result, REMICADE patients may require as few as six treatments each year.

Important Safety Information

There are reports of serious infections, including tuberculosis (TB), sepsis and pneumonia. Some of these infections have been fatal. Tell your doctor if you have had recent or past exposure to people with TB. Your doctor will evaluate you for TB and perform a TB test. If you have latent (inactive) TB, your doctor should begin TB treatment before you start REMICADE. REMICADE can lower your ability to fight infections, so if you are prone to or have a history of infections, or de
'/>"/>